The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature.

IF 5.8 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Thyroid Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI:10.1089/thy.2024.0271
Daniël J van de Berg, Pedro M Rodriguez Schaap, Faridi S Jamaludin, Hanneke M van Santen, Sarah C Clement, Menno R Vriens, A S Paul van Trotsenburg, Christiaan F Mooij, Eveline Bruinstroop, Schelto Kruijff, Robin P Peeters, Frederik A Verburg, Romana T Netea-Maier, Els J M Nieveen van Dijkum, Joep P M Derikx, Anton F Engelsman
{"title":"The Definition of Recurrence of Differentiated Thyroid Cancer: A Systematic Review of the Literature.","authors":"Daniël J van de Berg, Pedro M Rodriguez Schaap, Faridi S Jamaludin, Hanneke M van Santen, Sarah C Clement, Menno R Vriens, A S Paul van Trotsenburg, Christiaan F Mooij, Eveline Bruinstroop, Schelto Kruijff, Robin P Peeters, Frederik A Verburg, Romana T Netea-Maier, Els J M Nieveen van Dijkum, Joep P M Derikx, Anton F Engelsman","doi":"10.1089/thy.2024.0271","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Recurrence is a key outcome to evaluate the treatment effect of differentiated thyroid carcinoma (DTC). However, no consistent definition of recurrence is available in current literature or international guidelines. Therefore, the primary aim of this systematic review was to delineate the definitions of recurrence of DTC, categorized by total thyroidectomy with radioactive iodine ablation (RAI), total thyroidectomy without RAI and lobectomy, to assess if there is a generally accepted definition among these categories. <b><i>Methods:</i></b> This study adhered to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. In December 2023, a systematic literature search in MEDLINE and EMBASE was performed for studies reporting on the recurrence of DTC, from January 2018 to December 2023. Studies that did not provide a definition were excluded. Primary outcome was the definition of recurrence of DTC. Secondary outcome was whether studies differentiated between recurrence and persistent disease. Two independent investigators screened the titles and abstracts, followed by full-text assessment and data extraction. The study protocol was registered in PROSPERO, CRD42021291753. <b><i>Results:</i></b> In total, 1450 studies were identified. Seventy studies met the inclusion criteria, including 69 retrospective studies and 1 randomised controlled trial (RCT). Median number of patients in the included studies was 438 (range 25-2297). In total, 17 studies (24.3%) reported on lobectomy, 4 studies (5.7%) on total thyroidectomy without RAI, and 49 studies (70.0%) with RAI. All studies defined recurrence using one or a combination of four diagnostic modalities cytology/pathology, imaging studies, thyroglobulin (-antibodies), and a predetermined minimum tumor-free time span. The most common definition of recurrence following lobectomy was cytology/pathology-proven recurrence (47.1% of this subgroup), following total thyroidectomy with RAI was cytology/pathology-proven recurrence and/or anomalies detected on imaging studies (22.4% of this subgroup). No consistent definition was found following total thyroidectomy without RAI. Nine studies (12.9%) differentiated between recurrence and persistent disease. <b><i>Conclusion:</i></b> Our main finding is that there is no universally accepted definition for recurrence of DTC in the current studies across any of the treatment categories. The findings of this study will provide the basis for a future, international Delphi-based proposal to establish a universally accepted definition of recurrence of DTC. A uniform definition could facilitate global discussion and enhance the assessment of treatment outcomes regarding recurrence of DTC.</p>","PeriodicalId":23016,"journal":{"name":"Thyroid","volume":" ","pages":"1324-1334"},"PeriodicalIF":5.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thyroid","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1089/thy.2024.0271","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Recurrence is a key outcome to evaluate the treatment effect of differentiated thyroid carcinoma (DTC). However, no consistent definition of recurrence is available in current literature or international guidelines. Therefore, the primary aim of this systematic review was to delineate the definitions of recurrence of DTC, categorized by total thyroidectomy with radioactive iodine ablation (RAI), total thyroidectomy without RAI and lobectomy, to assess if there is a generally accepted definition among these categories. Methods: This study adhered to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. In December 2023, a systematic literature search in MEDLINE and EMBASE was performed for studies reporting on the recurrence of DTC, from January 2018 to December 2023. Studies that did not provide a definition were excluded. Primary outcome was the definition of recurrence of DTC. Secondary outcome was whether studies differentiated between recurrence and persistent disease. Two independent investigators screened the titles and abstracts, followed by full-text assessment and data extraction. The study protocol was registered in PROSPERO, CRD42021291753. Results: In total, 1450 studies were identified. Seventy studies met the inclusion criteria, including 69 retrospective studies and 1 randomised controlled trial (RCT). Median number of patients in the included studies was 438 (range 25-2297). In total, 17 studies (24.3%) reported on lobectomy, 4 studies (5.7%) on total thyroidectomy without RAI, and 49 studies (70.0%) with RAI. All studies defined recurrence using one or a combination of four diagnostic modalities cytology/pathology, imaging studies, thyroglobulin (-antibodies), and a predetermined minimum tumor-free time span. The most common definition of recurrence following lobectomy was cytology/pathology-proven recurrence (47.1% of this subgroup), following total thyroidectomy with RAI was cytology/pathology-proven recurrence and/or anomalies detected on imaging studies (22.4% of this subgroup). No consistent definition was found following total thyroidectomy without RAI. Nine studies (12.9%) differentiated between recurrence and persistent disease. Conclusion: Our main finding is that there is no universally accepted definition for recurrence of DTC in the current studies across any of the treatment categories. The findings of this study will provide the basis for a future, international Delphi-based proposal to establish a universally accepted definition of recurrence of DTC. A uniform definition could facilitate global discussion and enhance the assessment of treatment outcomes regarding recurrence of DTC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分化型甲状腺癌复发的定义:文献系统性综述。
背景 复发是评估分化型甲状腺癌(DTC)治疗效果的关键结果。然而,目前的文献或国际指南中并没有关于复发的统一定义。因此,本系统性综述的主要目的是按照甲状腺全切除术加放射性碘消融术(RAI)、甲状腺全切除术加放射性碘消融术(RAI)和甲状腺叶切除术来划分 DTC 复发的定义,以评估这些类别中是否存在公认的定义。方法 本研究遵循 2020 年 PRISMA 声明。2023 年 12 月,在 MEDLINE 和 EMBASE 中对 2018 年 1 月至 2023 年 12 月期间报告 DTC 复发的研究进行了系统文献检索。未提供定义的研究被排除在外。主要结果是DTC复发的定义。次要结果是研究是否区分了复发和持续性疾病。两名独立研究者筛选了标题和摘要,随后进行了全文评估和数据提取。研究方案已在 PROSPERO 注册,编号为 CRD42021291753。结果 共确定了 1450 项研究。有 70 项研究符合纳入标准,其中包括 69 项回顾性研究和 1 项 RCT 研究。纳入研究的患者人数中位数为 438 人(范围在 25 - 2297 之间)。17项研究(24.3%)报告了甲状腺叶切除术,4项研究(5.7%)报告了不使用RAI的全甲状腺切除术,49项研究(70.0%)报告了使用RAI的全甲状腺切除术。所有研究均采用细胞学/病理学、影像学、甲状腺球蛋白(抗体)、预定的最短无瘤时间跨度等四种诊断方式中的一种或组合来定义复发。甲状腺叶切除术后最常见的复发定义是细胞学/病理学证实的复发(占该亚组的47.1%),甲状腺全切除术加RAI后最常见的复发定义是细胞学/病理学证实的复发和/或影像学检查发现的异常(占该亚组的22.4%)。在不使用 RAI 的全甲状腺切除术中,没有发现一致的定义。9项研究(12.9%)区分了复发和顽固性疾病。结论 我们的主要发现是,在目前的研究中,任何治疗类别的 DTC 复发都没有公认的定义。本研究的发现将为未来基于德尔菲法的国际提案提供基础,以确立一个普遍接受的 DTC 复发定义。统一的定义可促进全球讨论,加强对 DTC 复发治疗结果的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thyroid
Thyroid 医学-内分泌学与代谢
CiteScore
12.30
自引率
6.10%
发文量
195
审稿时长
6 months
期刊介绍: This authoritative journal program, including the monthly flagship journal Thyroid, Clinical Thyroidology® (monthly), and VideoEndocrinology™ (quarterly), delivers in-depth coverage on topics from clinical application and primary care, to the latest advances in diagnostic imaging and surgical techniques and technologies, designed to optimize patient care and outcomes. Thyroid is the leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. The Journal delivers the latest findings on topics from primary care to clinical application, and is the exclusive source for the authoritative and updated American Thyroid Association (ATA) Guidelines for Managing Thyroid Disease.
期刊最新文献
Examining Why Thyroid Cancer Incidence Is High in Women. Differential Ultrasound Rates Mirror Sex Disparities in Thyroid Cancer. Irwin Klein, MD (1946-2024). Surgical and Pathological Challenges in Thyroidectomy after Thermal Ablation of Thyroid Nodules. Association Between Environmental Air Pollution and Thyroid Cancer and Nodules: A Systematic Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1